Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473649 | 0.94 | KMT2A (0.47) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL16032495 | 0.93 | KMT2A (0.47) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL16032497 | 0.93 | KMT2A (0.47) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL16032494 | 0.93 | KMT2A (0.47) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL9185202 | 0.89 | KMT2A (0.46) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| Ammonia Solution, Strong SCHEMBL9182347 | 0.88 | KMT2A (0.45) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL5768492 | 0.87 | NPFFR1 (0.48) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL2268507 | 0.87 | NPFFR1 (0.48) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL4675629 | 0.85 | KMT2A (0.47) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E | |
| SCHEMBL34474659 | 0.84 | KMT2A (0.44) | NPFFR1NPFFR2KMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138843-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-02-09 | — | — | US | disclosed |
| EP-0812838-B1 | PYRIDONECARBOXYLIC ACID DERIVATIVE SUBSTITUTED BY BICYCLIC AMINO GROUP, ESTER THEREOF, SALT THEREOF, AND BICYCLIC AMINE AS INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-5990106-A | ANTIBIOTICS; 3-AZABICYCLO(3.2.0)HEPT-3-YL GROUP JOINED AT GIVEN POSITION OF A PYRIDONECARBOXYLIC ACID RESIDUE, SUCH AS 7-(1-AMINO-3-AZABICYCLO(3.2.0)HEPT-3-YL)-1-CYCLOPROPYL-6,8-DIFLUORO-1,4 -DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1999-11-23 | — | — | US | disclosed |
| EP-0812838-A1 | PYRIDONECARBOXYLIC ACID DERIVATIVE SUBSTITUTED BY BICYCLIC AMINO GROUP, ESTER THEREOF, SALT THEREOF, AND BICYCLIC AMINE AS INTERMEDIATE THEREFOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | NPFFR1 3277/4885NPFFR2 2708/4885KMT2A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.